Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A precise volume status assessment is critical to improve outcome of patients on dialysis. Yet, accurate assessment of fluid status remains a challenge. Currently, this is performed by clinical evaluation and regular weight measurements before and after dialysis, which is not always accurate. Moreover, bioimpedance technology is used in some centers for quantitative assessment of total body water. This approach has been validated for the assessment of volume status in dialysis patients, but requires the acquisition of specific tools and is time consuming. So far, no biomarker has been validated to quantify volume status in dialysis patients. Application of biomarkers might contribute to a better dialysis prescription and therefore to outcome improvement in dialysis. The investigators aim to investigate the role of a novel biomarkers (sCD146) to assess volume status in dialysis patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hemodialysis patients | A total of 30 patients - measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker |
| |
| Peritoneal dialysis patients | A total of 15 patients - measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bioelectrical impedance measurement and biomarker measurement | Device | Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level |
|
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of sCD146 level with overhydration assessed by bioimpedance technology | For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months | 3 weeks to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of sCD146 level measured after dialysis and ultrafiltration rate | for hemodialysis patients measurements will be concluded within 3 weeks | 3 weeks |
| Correlation of sCD146 level and clinical evaluation of volume status |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with end stage renal failure on hemodialysis and peritoneal dialysis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephan Segerer, MD | University Hospital Zürich, Zürich, Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Zürich | Zurich | 8901 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months
| 3 weeks to 3 months |
| Correlation of sCD146 level and level of NT-proBNP | For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months | 3 weeks to 3 months |
| Correlation of sCD146 level and mortality as assessed prospectively in 6 months follow-up | 6 months |
| Correlation of sCD146 level and hospitalizations as assessed prospectively in 6 months follow-up | 6 months |
| Correlation of sCD146 level and cardiovascular complications as assessed prospectively in 6 months follow-up | 6 months |
| Correlation of sCD146 level and shunt complications as assessed prospectively in 6 months follow-up | 6 months |